Thomas Smith Analyst Performance

Thomas Smith is a stock analyst at Leerink Partners in the medical sector, covering 12 publicly traded companies. Over the past year, Thomas Smith has issued 2 stock ratings, including buy and hold recommendations. While full access to Thomas Smith's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Thomas Smith's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

15 Last 7 Years

Buy Recommendations

66.67% 10 Buy Ratings

Companies Covered

12 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	66.7%	10 ratings
Hold	33.3%	5 ratings
Sell	0.0%	0 ratings

Out of 15 total stock ratings issued by Thomas Smith at Leerink Partners, the majority (66.7%) have been Buy recommendations, followed by 33.3% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  MLTX

  Aug 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  LABP

  Oct 2021

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	12 companies

Thomas Smith, an analyst at Leerink Partners, currently covers 12 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 12 companies	100.0%

Thomas Smith of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 6 companies	50.0%
PHARMACEUTICAL PREPARATIONS 3 companies	25.0%
BIOTECHNOLOGY 2 companies	16.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 1 company	8.3%

Thomas Smith's Ratings History at Leerink Partners

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
ABVX Abivax	7/23/2025	Set Price Target	$65.45	$74.00	Outperform	$0.00 00.00% ROI
EQ Equillium	3/28/2025	Reiterated Rating	$0.49	$1.00	Market Perform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.